effect of B blocker was first evaluated in patient with cardiomyopathy not induced by ischemia and idiopathic which as the most common causes of cardiomyopathy. Effect of BB on Thalassemia cardiomyopathy was evaluated in this study

In this clinical trial, 45 patients with thalassemia cardiomyopathy were randomized to receive either metoprolol (n = 26) or placebo (n = 19). Echocardiography and 6 minute walk test was performed at baseline and repeated after 6 months and the values were compared.

Inclusion Criteria:

• documented LVEF < 50% by echocardiography
• B thalassemia
• No decompensated heart failure for at least 4 weeks (hospitalization for CHF, worsening lower extremity edema, worsening dyspnea on exertion, , and orthopnea)
• have no evidence of acute myocarditis and
• hemoglobin level above 7 gr⁄dL.

Exclusion Criteria:

• pulse rate below 60/min
• systolic blood pressure less than 90 mmHg
• evidence of peripheral vascular disease
• major depression, history of asthma, PR interval more than 240 msec, second or third degree AV block
• major medical diseases including diabetes mellitus requiring insulin injection, hypothyroidism, hypoparathyroidism, chronic renal failure (glomerular filtration rate below 30 ml/min), hepatic cirrhosis, hepatitis-B and hepatitis-C, positive tests for human immunodeficiency virus, and other hemoglobinopathies